1 Duijf PHG, Nanayakkara D, Nones K, et al. Mechanisms of genomic instability in breast cancer. Trends Mol Med.2019;25(7):595–611.
2 Goel S, Wang Q, Watt A C, et al. Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors[J]. Cancer Cell, 2016, 29(3):255-269.
3 Yasunaga M. Antibody Therapeutics and Immunoregulation in Cancer and Autoimmune Disease[J]. https://doi.org/ 10.1016/j.semcancer.2019.06.001
4 Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19(3):133–50.
5 Krishnamurti U, Wetherilt C S, Yang J, et al. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor–positive breast cancers ☆[J]. Human Pathology, 2017, 64:7-12.
6 Hou Y, Nitta H, Wei L, et al. PD-L1 expression and CD8-positive T cells are associated with favorable survival in HER2-positive invasive breast cancer[J]. Breast J. 2018;24(6):911-919
7 Vihervuori H, Autere TA, Repo H,et al. Tumor infiltrating lymphocytes and CD8+ T cells predict survival of triple-negative breast cancer[J]. Journal of Cancer Research and Clinical Oncology,2019 ,145(12):3105-3114)
8 Noske A, Mobus V, Weber K, et al. Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study[J]. Eur J Cancer, 2019; 114:76–88.
9 Katsuhiko S, Riki O, Shinsuke S, et al. Prognostic value of Cox-2 and PD-L1 expression and its relationship with tumor-infiltrating lymphocytes in resected lung adenocarcinoma[J]. Cancer Management and Research, 2017, Volume 9:741-750.
10 Bense RD, Sotiriou C, Piccart- Gebhart MJ, et al. Relevance of tumor-infiltrating immune cell composition and functionality for diseaseoutcome in breast cancer[J]. J Natl Cancer Inst, 2017, 109(1):7-15.
11 Ali HR, Chlon L, Pharoah PD, et al. Patterns of immune infiltration in breast cancer and their clinical implications: a gene-expressionbased retrospective study[J]. PLoS Med, 2016, 13(12): e1002194.
12 Barnes TA, Amir E. HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer[J]. Br J Cancer, 2017, 117(4):451-460.
13 Raphael J, Gong IY, Nofech-Mozes S, et al. Tumour infiltrating lymphocytes and stromal CD68 in early stage HER- 2 positive breast cancer[J]. J Clin Pathol, 2016, 69(6):552-555.
14 Solinas C, Ceppi M, Lambertini M, et al. Tumor-infiltrating lymphocytes in patients with HER- 2- positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab,lapatinib or their combination: a meta- analysis of randomized controlled trials[J]. Cancer Treat Rev, 2017, 57:8-15.
15 Baptista MZ, Sarian LO, Derchain SF, et al. Prognostic significance of PD‐L1 and PD‐L2 in breast cancer. Hum Pathol. 2016,47:78-84.
16 Cimino‐Mathews A, Thompson E, Taube JM, et al. PD‐L1 (B7–H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Hum Pathol. 2016;47(1):52‐63
17 Dill EA, Gru AA, Atkins KA et al. PD‐L1 expression and intratumoral heterogeneity across breast cancer subtypes and stages: an assessment of 245 primary and 40 metastatic tumors. Am J Surg Pathol. 2017;41(3):334-342.
18 Velcheti V, Schalper KA, Carvajal DE, et al. Programmed death ligand‐1 expression in non‐small cell lung cancer. Lab. Invest. 2014; 94:107-116.
19 Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7–H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 2012;4(127):127ra37
20 Mittendorf EA, Philips AV, Meric-Bernstam F, et al. PD‐L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014; 2:361-370.